Bovine Lactoferricin Directly Kills Tumor Cells In Vivo, Not Just Through Immune Activation

Bovine lactoferricin (LfcinB) directly killed cancer cells in mice through a cytotoxic mechanism rather than immune system activation, demonstrating a direct antitumor effect of this milk-derived peptide.

Eliassen, Liv Tone et al.·Anticancer research·2002·Moderate EvidenceAnimal StudyAnimal Study
RPEP-00725Animal StudyModerate Evidence2002RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Bovine lactoferricin inhibited tumor growth in immunodeficient mice, proving a direct cytotoxic antitumor mechanism independent of immune system activation, likely through cancer cell membrane disruption.

Key Numbers

How They Did This

Animal study using immunodeficient mice (lacking functional immune systems) to distinguish direct antitumor from immune-mediated effects. LfcinB treatment of tumor-bearing mice with tumor growth measurement.

Why This Research Matters

A natural peptide that directly kills cancer cells without requiring an immune system could work even in immunocompromised cancer patients — a population where immunotherapy-based approaches fail.

The Bigger Picture

Cancer therapies that work independently of the immune system complement immunotherapy. LfcinB's direct killing ability means it could help even patients whose immune systems are compromised by cancer or chemotherapy.

What This Study Doesn't Tell Us

Specific tumor types tested may not represent all cancers. The exact membrane disruption mechanism in cancer cells needs further characterization. Dosing and delivery for clinical use not established.

Questions This Raises

  • ?Can LfcinB selectivity for cancer versus normal cells be optimized?
  • ?Would LfcinB complement chemotherapy or immunotherapy?
  • ?Can oral lactoferrin generate enough LfcinB for antitumor effects?

Trust & Context

Key Stat:
Immune-independent LfcinB killed tumors in mice without immune systems — direct cancer cell killing, not immune enhancement, is the primary mechanism
Evidence Grade:
Moderate evidence from a well-designed experiment using immunodeficient mice to definitively distinguish direct from immune-mediated antitumor effects.
Study Age:
Published in 2002. Lactoferricin's direct antitumor mechanism has been further characterized, with applications in cancer peptide therapy.
Original Title:
Evidence for a direct antitumor mechanism of action of bovine lactoferricin.
Published In:
Anticancer research, 22(5), 2703-10 (2002)
Database ID:
RPEP-00725

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Can a milk peptide fight cancer?

In mice, yes. Lactoferricin from milk directly killed cancer cells by disrupting their membranes — similar to how it kills bacteria. It didn't need the immune system to work, which was the breakthrough finding.

Could this help cancer patients?

Potentially. Since it works without an immune system, it could help even patients whose immunity is weakened by cancer or chemotherapy. But scaling from mice to human cancer treatment requires much more research.

Read More on RethinkPeptides

Cite This Study

RPEP-00725·https://rethinkpeptides.com/research/RPEP-00725

APA

Eliassen, Liv Tone; Berge, Gerd; Sveinbjørnsson, Baldur; Svendsen, John S; Vorland, Lars H; Rekdal, Øystein. (2002). Evidence for a direct antitumor mechanism of action of bovine lactoferricin.. Anticancer research, 22(5), 2703-10.

MLA

Eliassen, Liv Tone, et al. "Evidence for a direct antitumor mechanism of action of bovine lactoferricin.." Anticancer research, 2002.

RethinkPeptides

RethinkPeptides Research Database. "Evidence for a direct antitumor mechanism of action of bovin..." RPEP-00725. Retrieved from https://rethinkpeptides.com/research/eliassen-2002-evidence-for-a-direct

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.